Skip to main content
HLB bioStep Co.,Ltd. logo

HLB bioStep Co.,Ltd. — Investor Relations & Filings

Ticker · 278650 ISIN · KR7278650007 KO Professional, scientific and technical activities
Open in API
Filings indexed 326 across all filing types
Latest filing 2024-10-29 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 278650

About HLB bioStep Co.,Ltd.

http://hlbbiostep.com/en/

HLB bioStep Co.,Ltd. is a non-clinical Contract Research Organization (CRO) that provides a range of testing services to pharmaceutical companies and bio ventures. The company's core services support new drug development and include efficacy testing, pharmacokinetic/toxicokinetic (PK/TK) studies, and toxicology evaluations. A key area of specialization is veterinary medicine; HLB bioStep is an institution approved to conduct non-clinical tests and clinical trials for veterinary drugs. It also offers consulting services for regulatory approval procedures. The company utilizes various platform technologies, such as cell-enzyme-based screening and xenograft assays, and provides a comprehensive 'One-Stop Service' that leverages its experience in building laboratory facilities.

Recent filings

Filing Released Lang Actions
[기재정정]주요사항보고서(전환사채권발행결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matters Report' (주요사항보고서) regarding the issuance of convertible bonds (전환사채권 발행결정) and includes a 'Correction Report' (정정신고) header. This type of filing is a standard regulatory disclosure in the Korean market (DART system) for significant corporate financing events, specifically capital structure changes involving debt-to-equity instruments. It does not fit into the 'Annual Report' or 'Earnings Release' categories, but rather falls under 'Capital/Financing Update' as it details the terms, purpose, and conditions of a convertible bond issuance.
2024-10-29 Korean
전환가액의조정
Capital/Financing Update Classification · 100% confidence The document is an official regulatory filing from HLB Life Science Step (HLB바이오스텝) regarding the adjustment of the conversion price (전환가액의 조정) for convertible bonds. This type of filing is a standard corporate disclosure related to capital structure changes and financial instruments. Since it specifically details the adjustment of conversion prices due to market price fluctuations, it falls under the category of Capital/Financing Update (CAP).
2024-10-14 Korean
신탁계약에의한취득상황보고서
Transaction in Own Shares Classification · 100% confidence The document is a 'Report on Acquisition Status by Trust Agreement' (신탁계약등에의한취득상황보고서) filed by HLB BioStep. It details the company's acquisition of its own shares through a trust contract with Samsung Securities. This type of filing is a standard regulatory disclosure in South Korea regarding share buybacks, which falls under the category of 'Transaction in Own Shares'.
2024-08-26 Korean
반기보고서 (2024.06)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Semi-Annual Report' (반기보고서) for HLB bioStep Co., Ltd. for the period of January 1, 2024, to June 30, 2024. It contains comprehensive financial information, business descriptions, and management disclosures required for a periodic report. According to the filing definitions, a comprehensive financial report for a period shorter than a full fiscal year is classified as an Interim / Quarterly Report (IR). H1 2024
2024-08-14 Korean
전환가액의조정
Capital/Financing Update Classification · 100% confidence The document is an official regulatory filing from HLB Life Science (HLB바이오스텝) regarding the adjustment of the conversion price (전환가액의 조정) for convertible bonds. This type of filing is a standard corporate disclosure related to capital structure changes and financing instruments. In the provided taxonomy, 'Capital/Financing Update' (CAP) is the most accurate category for adjustments to conversion prices of debt instruments.
2024-07-15 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report on Large Shareholding' (주식등의 대량보유상황보고서), which is a standard regulatory filing in South Korea (often referred to as a 5% rule filing). It details changes in share ownership by a major shareholder (Korea Securities Finance Corp) in HLB BioStep. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema, as it tracks significant ownership thresholds and changes.
2024-07-10 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.